325.46MMarket Cap-5.88P/E (TTM)
1.700High1.640Low1.08MVolume1.680Open1.680Pre Close1.80MTurnover0.55%Turnover RatioLossP/E (Static)197.85MShares3.94052wk High-0.84P/B321.86MFloat Cap1.47052wk Low--Dividend TTM195.66MShs Float120.960Historical High--Div YieldTTM3.57%Amplitude0.700Historical Low1.662Avg Price1Lot Size
Esperion Therapeutics Stock Forum
FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
Thursday, 20th March at 8:00 am
– Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia –
– Establishes Pediatric Path Forward to Start and Complete Phase 3 Trial and Se...
Written by MarketBeat
March 15, 2025 Cantor Fitzgerald Brokers Raise Earnings Estimates for ESPR
Cantor Fitzgerald raised their FY2025 earnings per share estimates for Esperion Therapeutics in a report released on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now forecasts tha...
😅😅😅😅😅😅😅😅😅😅
Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst . Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target.
Thomas Shrader has given his Buy rating due to a combination ...
No comment yet